Introduction and commentary: paving the way for biosimilars in oncology, part 2: focus on safety and clinical trial considerations

Affiliations

Editorial

Jame Abraham. Semin Oncol. 2014 Feb.

. 2014 Feb:41 Suppl 1:S1-2.

doi: 10.1053/j.seminoncol.2013.12.003. Epub 2013 Dec 6.

¹ Director, Breast Oncology Program Taussig Cancer Institute Cleveland Clinic Cleveland, OH. Electronic address: abrahaj5@ccf.org.

No abstract available

Similar articles

Introduction and commentary: Paving the way for biosimilars in oncology.
Abraham J. Abraham J. Semin Oncol. 2013 Dec;40 Suppl 1:S1-4. doi: 10.1053/j.seminoncol.2013.09.014. Epub 2013 Oct 4. Semin Oncol. 2013. PMID: 24267943 No abstract available.
Developing clinical trials for biosimilars.
Bui LA, Taylor C. Bui LA, et al. Semin Oncol. 2014 Feb;41 Suppl 1:S15-25. doi: 10.1053/j.seminoncol.2013.12.002. Epub 2013 Dec 7. Semin Oncol. 2014. PMID: 24560024 Review.
Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH, Jacobs IA. Rak Tkaczuk KH, et al. Semin Oncol. 2014 Apr;41 Suppl 3:S3-S12. doi: 10.1053/j.seminoncol.2014.03.008. Epub 2014 Mar 13. Semin Oncol. 2014. PMID: 24767633 Review.
Biosimilar safety considerations in clinical practice.
Choy E, Jacobs IA. Choy E, et al. Semin Oncol. 2014 Feb;41 Suppl 1:S3-14. doi: 10.1053/j.seminoncol.2013.12.001. Epub 2013 Dec 6. Semin Oncol. 2014. PMID: 24560025
Introduction and commentary: Paving the way for biosimilars in oncology, part 3: Clinical and economic impact of oncology biosimilars.
Abraham J. Abraham J. Semin Oncol. 2014 Apr;41 Suppl 3:S1-2. doi: 10.1053/j.seminoncol.2014.03.010. Epub 2014 Mar 14. Semin Oncol. 2014. PMID: 24767631 No abstract available.